CompoundedRxClaimsAudit / report
CompoundedRxClaimsAudit report: https://www.demo-weightcare.example/semaglutide
Demo report on a fictional sample site.
37 / 100
5 of 9 checks need attention (3 high priority).
- ✓ Observed: compounded drugs marketed on the page (low): Compounded products are mentioned (GLP-1 / semaglutide / tirzepatide wording present).
- ✗ Observed: "not FDA-approved" statement for compounded drugs (high): Compounded drugs are marketed but no "not FDA-approved" statement was found.
- ✗ Observed: generic, "same as" or "clinically proven" wording (high): Found: "same active ingredient as".
- ✓ Observed: "FDA-approved" wording on a page that markets compounded drugs (high): No "FDA-approved" wording alongside compounded products.
- ✗ Observed: brand-name drug trademarks on a compounded-drug page (medium): Brand names on the page: Ozempic, Wegovy.
- ✓ Observed: prescription and eligibility wording (medium): Prescription or provider-evaluation wording is present.
- ✗ Observed: risk or side-effect information (high): Prescription drugs are marketed but no side-effect or risk wording was found.
- ✗ Observed: LegitScript certification seal (low): No LegitScript seal found.
- ✓ Observed: medical-supervision and state-licensure statements (low): Supervision wording (medical director, physician-supervised) present. State availability or licensure wording present.
Automated observations of the publicly served HTML of one page (text, links and scripts; content in images, videos or added later by JavaScript may not be seen). Context: FD&C Act sections 503A and 503B (21 U.S.C. 353a, 353b: conditions for compounded drugs), section 502(bb) (21 U.S.C. 352(bb): a compounded drug is misbranded if its advertising or promotion is false or misleading), and FDA's statements that compounded drugs are not FDA-approved; state medical and pharmacy boards set supervision and licensure rules. Not legal advice and not a compliance certification.